(IN BRIEF) Roche has released positive long-term follow-up data from the Phase III KATHERINE study, evaluating Kadcyla® (trastuzumab emtansine) as…
Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO,…